Actinogen Medical (ASX:ACW) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ACW 주식 개요

생명공학 회사인 액티노젠 메디컬은 호주에서 뇌 코르티솔 조절 장애와 관련된 신경 및 신경정신 질환 치료제를 개발하는 회사입니다.

ACW 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 24.31% 증가할 것으로 예상됩니다.

위험 분석

지난 5년간 매년 수익이 11.8% 씩 감소했습니다.

최근 3개월간 주가 변동폭 심해

지난 1년 동안 주주가 희석되었습니다.

의미 있는 수익이 없습니다. ( A$5M )

Actinogen Medical Limited 경쟁사

Aroa Biosurgery

ASX:ARX

AU$210.0m

Dimerix

ASX:DXB

AU$288.9m

Imugene

ASX:IMU

AU$373.3m

Beroni Group

NSX:BTG

AU$75.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Actinogen Medical
과거 주가
현재 주가	AU$0.06
52주 최고치	AU$0.07
52주 최저치	AU$0.015
베타	1.91
11개월 변경	106.90%
3개월 변경 사항	106.90%
1년 변경 사항	46.34%
33년 변화	-47.83%
5년 변화	445.50%
IPO 이후 변화	-92.68%

최근 뉴스 및 업데이트

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Apr 30

Recent updates

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Aug 09

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Apr 07

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Oct 24

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Jul 11

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Mar 27

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Jan 07

주주 수익률

	ACW	AU Biotechs	AU 마켓
7D	93.5%	-0.8%	-1.4%
1Y	46.3%	6.5%	6.5%

수익률 대 산업: ACW 지난 1년 동안 7.4 %를 반환한 Australian Biotechs 산업을 초과했습니다.

수익률 대 시장: ACW 지난 1년 동안 8.3 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is ACW's price volatile compared to industry and market?
ACW volatility
ACW Average Weekly Movement	19.8%
Biotechs Industry Average Movement	11.5%
Market Average Movement	8.3%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	3.3%

안정적인 주가: ACW 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ACW 의 주간 변동성( 16% )은 지난 1년 동안 안정적이었지만 여전히 Australian 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1999	n/a	Steve Gourlay	www.actinogen.com.au

생명공학 회사인 액티노젠 메디컬은 호주에서 뇌 코르티솔 조절 장애와 관련된 신경 및 신경정신 질환 치료제를 개발하는 회사입니다. 이 회사는 중추신경계, 인지 장애를 동반한 우울증, 알츠하이머병, 취약성 X 증후군의 불안, 수면 및 행동 문제를 표적으로 하는 임상 2상 시험 중인 11ß-HSD1 효소 억제제인 자나멤(Xanamem)을 개발 중입니다. 이 회사는 이전에 Actinogen Limited로 알려졌으며 2015년 11월에 Actinogen Medical Limited로 사명을 변경했습니다.

Actinogen Medical Limited 기본 사항 요약

Actinogen Medical 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ACW 기본 통계
시가총액	AU$160.98m
수익(TTM)	-AU$14.87m
수익(TTM)	AU$4.79m

33.6x

P/S 비율

-10.8x

P/E 비율

ACW 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ACW 손익 계산서(TTM)
수익	AU$4.79m
수익 비용	AU$0
총 이익	AU$4.79m
기타 비용	AU$19.66m
수익	-AU$14.87m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.0055
총 마진	100.00%
순이익 마진	-310.26%
부채/자본 비율	0%

ACW 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ACW 주식 개요

보상

위험 분석

Actinogen Medical Limited 경쟁사

ASX:ARX

AU$210.0m

ASX:DXB

AU$288.9m

ASX:IMU

AU$373.3m

NSX:BTG

AU$75.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

New major risk - Share price stability

Recent updates

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

New major risk - Share price stability

Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

Actinogen Medical Limited Announces CFO Changes

AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston

New minor risk - Share price stability

Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results

New minor risk - Shareholder dilution

Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?

New major risk - Financial position

Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention

We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 11%

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial

Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial

Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial

We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely

Price target increased to AU$0.15

Independent Non-Executive Director exercised options to buy AU$180k worth of stock.

MD, CEO & Director recently bought AU$94k worth of stock

Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results

Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression

Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD

MD, CEO & Director recently bought AU$128k worth of stock

Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem

Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn

Actinogen Medical Limited Completes Global Patent Family Grant

Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial

Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business

Actinogen Receives Positive Pre-IND FDA Advice for FXS

Actinogen Medical Receives Ethics Committee Approval for XanaMIA study

We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow

Actinogen Medical Limited Appoints Steven Gourlay as CEO

MD, CEO & Director John Ketelbey has left the company

MD, CEO & Director John Ketelbey has left the company

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome

How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?

Actinogen Medical Limited Announces Two New Clinical Trials

Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer

주주 수익률

가격 변동성

회사 소개

Actinogen Medical Limited 기본 사항 요약

33.6x